Dr. Shore discusses benefit of darolutamide combination therapy in nmCRPC

“I think this data are very compelling,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the takeaways of the study, “Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.